Antidepressants On Multiple Sclerosis: A Review Of In Vitro And In Vivo Models
Increased prevalence of depression has been observed among patients with multiple sclerosis (MS) and correlated with the elevated levels of proinflammatory cytokines and the overall deregulation of monoaminergic neurotransmitters that these patients exhibit. Antidepressants have proved effective not only in treating depression comorbid to MS, but also in alleviating numerous MS symptoms and even minimizing stress-related relapses. Therefore, these agents could prospectively prove beneficial as a complementary MS therapy.
This review aims at illustrating the underlying mechanisms involved in the beneficial clinical effects of antidepressants observed in MS patients.
Through a literature search we screened and comparatively assessed papers on the effects of antidepressant use both
Antidepressants were efficient in tackling numerous aspects of disease pathophysiology both